Evidence map›Paper›PMID 42194764›Full record

ReviewJournal of clinical medicine2026

Capivasertib as a Therapeutic Agent for Breast Cancer: Targeting AKT to Overcome Endocrine Resistance.

Christos Damaskos, Nikolaos Garmpis, Nikolaos Arkadopoulos, Nikolaos V Michalopoulos, Anna Garmpi, Miltiadis-Panagiotis Papandroudis, Eleni I Effraimidou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Christos DamaskosDepartment of Emergency Surgery, Laiko General Hospital, 11527 Athens, Greece.ORCID 0000-0002-5454-2564
Nikolaos GarmpisN.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0001-9980-0056
Nikolaos Arkadopoulos4th Department of Surgery, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Chaidari, 12462 Athens, Greece.
Nikolaos V MichalopoulosFirst Department of Propedeutic Surgery, Hippocration General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Anna Garmpi8th Department of Internal Medicine, Ygeia General Hospital, 15123 Athens, Greece.ORCID 0000-0003-0258-5965
Miltiadis-Panagiotis PapandroudisMedical School, University of Plovdiv, 4002 Plovdiv, Bulgaria.
Eleni I EffraimidouBreast Unit, First Surgical Department, University Hospital of Alexandroupolis, Democritus University of Thrace, Dragana, 68100 Alexandroupolis, Greece.ORCID 0000-0003-0129-5835

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AKT inhibitorsbreast cancerbreast tumorscapivasertibendocrine resistance

Identifiers

PMID42194764
PMCPMC13207011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.